Key result
Eltrombopag raises platelet counts and cuts bleeding risk vs placebo in pediatric chronic ITP.
Answers are grounded in this paper and cite their sources.
Demonstrates that eltrombopag increases platelet counts and limits bleeding in pediatric immune thrombocytopenia, highlighting its therapeutic value.
Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) in children. This oral, once-per-day therapy has shown favorable efficacy and adverse effect profiles in children. Two multicenter, double-blind, placebo controlled clinical trials (PETIT [Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)] and PETIT2 [Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body]) demonstrated efficacy in raising platelet counts, reducing bleeding, and reducing the need for concomitant ITP therapies with relatively few adverse effects. The most commonly reported drug-related adverse effects include headache, nausea, and hepatobiliary laboratory abnormalities. Long-term safety data in children are limited, and studies in adults have not revealed a clinically significant increased incidence of thrombosis, marrow fibrosis, or cataract formation. Eltrombopag has also been approved for treating refractory severe aplastic anemia (AA) and has potential for expanded use in ITP and severe AA as well as in other conditions associated with thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) conducted a review in Chronic immune thrombocytopenia (ITP). Eltrombopag vs. Placebo was evaluated on Raising platelet counts, reducing bleeding, and reducing the need for concomitant ITP therapies. Eltrombopag (once-daily oral therapy) demonstrated efficacy vs placebo in two pediatric chronic ITP trials by raising platelet counts and reducing bleeding and concomitant therapy needs.
Synapse has enriched 10 related papers. Consider them for comparative context: